MedTrace Logo

Fecal Microbiota Transplantation (FMT) in Recipients After Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT03720392 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-12-01

Study results available
· View outcomes & findings →

Summary

This research study is studying the role fecal microbiota transplantation may play in post-Hematopoietic Cell Transplantation (HCT) recipients

Conditions

  • Allogeneic Hematopoietic Cell Transplantation (HCT)

Interventions

DRUG

FMT

FMT is a process utilizing microbial components which are the good, healthy bacteria that would otherwise naturally occur in the body.

DRUG

Placebo

a harmless pill, medicine, or procedure prescribed more for the psychological benefit to the patient than for any physiological effect.

Sponsors & Collaborators

  • Zachariah Michael DeFilipp

    lead OTHER

Principal Investigators

  • Zachariah DeFilipp, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-15
Primary Completion
2020-05-28
Completion
2020-05-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03720392 on ClinicalTrials.gov